265 related articles for article (PubMed ID: 2557614)
1. Epstein-Barr virus/complement fragment C3d receptor (CR2) reacts with p53, a cellular antioncogene-encoded membrane phosphoprotein: detection by polyclonal anti-idiotypic anti-CR2 antibodies.
Barel M; Fiandino A; Lyamani F; Frade R
Proc Natl Acad Sci U S A; 1989 Dec; 86(24):10054-8. PubMed ID: 2557614
[TBL] [Abstract][Full Text] [Related]
2. Intracellular interaction of EBV/C3d receptor (CR2) with p68, a calcium-binding protein present in normal but not in transformed B lymphocytes.
Barel M; Gauffre A; Lyamani F; Fiandino A; Hermann J; Frade R
J Immunol; 1991 Aug; 147(4):1286-91. PubMed ID: 1831222
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal and anti-idiotypic anti-EBV/C3d receptor antibodies detect two binding sites, one for EBV and one for C3d on glycoprotein 140, the EBV/C3dR, expressed on human B lymphocytes.
Barel M; Fiandino A; Delcayre AX; Lyamani F; Frade R
J Immunol; 1988 Sep; 141(5):1590-5. PubMed ID: 2842398
[TBL] [Abstract][Full Text] [Related]
4. Epstein Barr virus/complement C3d receptor is an interferon alpha receptor.
Delcayre AX; Salas F; Mathur S; Kovats K; Lotz M; Lernhardt W
EMBO J; 1991 Apr; 10(4):919-26. PubMed ID: 1849076
[TBL] [Abstract][Full Text] [Related]
5. Nuclear localization of the Epstein-Barr virus/C3d receptor (CR2) in the human Burkitt B lymphoma cell, Raji.
Gauffre A; Viron A; Barel M; Hermann J; Puvion E; Frade R
Mol Immunol; 1992 Sep; 29(9):1113-20. PubMed ID: 1323059
[TBL] [Abstract][Full Text] [Related]
6. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.
Carel JC; Myones BL; Frazier B; Holers VM
J Biol Chem; 1990 Jul; 265(21):12293-9. PubMed ID: 1695627
[TBL] [Abstract][Full Text] [Related]
7. Purification of the Epstein-Barr virus/C3d complement receptor of human B lymphocytes: antigenic and functional properties of the purified protein.
Nemerow GR; Siaw MF; Cooper NR
J Virol; 1986 May; 58(2):709-12. PubMed ID: 2422399
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.
Pernegger G; Schulz TF; Hosp M; Myones BL; Petzer AL; Eigentler A; Böck G; Wick G; Dierich MP
Immunology; 1988 Oct; 65(2):237-41. PubMed ID: 2461345
[TBL] [Abstract][Full Text] [Related]
9. Identification of a spontaneously shed fragment of B cell complement receptor type two (CR2) containing the C3d-binding site.
Myones BL; Ross GD
Complement; 1987; 4(2):87-98. PubMed ID: 3497773
[TBL] [Abstract][Full Text] [Related]
10. CR2 complement receptor.
Cooper NR; Bradt BM; Rhim JS; Nemerow GR
J Invest Dermatol; 1990 Jun; 94(6 Suppl):112S-117S. PubMed ID: 2161885
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of the purified Epstein Barr virus/C3d receptor (CR2) into liposomes and demonstration of its dual ligand binding functions.
Mold C; Cooper NR; Nemerow GR
J Immunol; 1986 Jun; 136(11):4140-5. PubMed ID: 3009615
[TBL] [Abstract][Full Text] [Related]
12. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21).
Esparza I; Becherer JD; Alsenz J; De la Hera A; Lao Z; Tsoukas CD; Lambris JD
Eur J Immunol; 1991 Nov; 21(11):2829-38. PubMed ID: 1834472
[TBL] [Abstract][Full Text] [Related]
13. Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody.
Iida K; Nadler L; Nussenzweig V
J Exp Med; 1983 Oct; 158(4):1021-33. PubMed ID: 6225820
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and antigenic analysis of the Epstein Barr virus/C3d receptor (CR2).
Siaw MF; Nemerow GR; Cooper NR
J Immunol; 1986 Jun; 136(11):4146-51. PubMed ID: 3009616
[TBL] [Abstract][Full Text] [Related]
15. Binding sites of the Epstein-Barr virus and C3d receptor (CR2, CD21) for its three intracellular ligands, the p53 anti-oncoprotein, the p68 calcium binding protein and the nuclear p120 ribonucleoprotein.
Barel M; Balbo M; Gauffre A; Frade R
Mol Immunol; 1995 Apr; 32(6):389-97. PubMed ID: 7753047
[TBL] [Abstract][Full Text] [Related]
16. Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d.
Hutt-Fletcher LM; Fowler E; Lambris JD; Feighny RJ; Simmons JG; Ross GD
J Immunol; 1983 Mar; 130(3):1309-12. PubMed ID: 6218205
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2).
Nemerow GR; Wolfert R; McNaughton ME; Cooper NR
J Virol; 1985 Aug; 55(2):347-51. PubMed ID: 2410629
[TBL] [Abstract][Full Text] [Related]
18. EBV/C3d receptor (CR2) interacts by its intracytoplasmic carboxy-terminal domain and two distinct binding sites with the p53 anti-oncoprotein and the p68 calcium-binding protein.
Frade R; Gauffre A; Hermann J; Barel M
J Immunol; 1992 Nov; 149(10):3232-8. PubMed ID: 1431101
[TBL] [Abstract][Full Text] [Related]
19. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.
Nemerow GR; Mold C; Schwend VK; Tollefson V; Cooper NR
J Virol; 1987 May; 61(5):1416-20. PubMed ID: 3033269
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction.
Molina H; Brenner C; Jacobi S; Gorka J; Carel JC; Kinoshita T; Holers VM
J Biol Chem; 1991 Jul; 266(19):12173-9. PubMed ID: 1712014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
